Literature DB >> 21571386

Residual metabolic tumor activity after chemo-radiotherapy is mainly located in initially high FDG uptake areas in rectal cancer.

Jørgen van den Bogaard1, Marco H M Janssen, G Janssens, Jeroen Buijsen, Brigitte Reniers, Philippe Lambin, Guido Lammering, Michel C Ollers.   

Abstract

PURPOSE: Recent literature suggests that tumor cells and areas within tumors with a high initial FDG uptake might be more resistant to (chemo)radiotherapy ((C)RT). This study was undertaken to test this hypothesis in rectal cancer using rigid and non-rigid image registration. PATIENTS AND METHODS: Twenty-eight patients, diagnosed with locally advanced rectal cancer and referred for pre-operative treatment with CRT were included in this study. All patients underwent FDG-PET-CT imaging prior to and after CRT. Rigid and non-rigid image registration was performed to compensate organ deformations between the pre- and post-treatment PET-CT scans. The tumor was contoured on both PET-scans using SUV iso-contouring based on the SBR-method. The voxels with residual increased FDG uptake were studied and correlated to their pre-treatment FDG uptake level. Two SUV-volume-histograms were made based on the pre-treatment PET-data, one for the voxels within the pre-treatment tumor PET-based iso-contour and one for the voxels within the PET-based iso-contour of the residual tumor non-rigidly registered onto the pre-treatment scan.
RESULTS: For the voxels with a pre-treatment FDG uptake of >50% of SUV(max), 70.6±5.6% of the voxels were still metabolic active in the residual tumor, whereas for voxels with an FDG uptake of <50% of SUV(max) only 51.1±6.7% were present in the metabolic active residual tumor.
CONCLUSION: This study presents areas in rectal tumors with an initially high FDG uptake to be most likely to show residual disease after CRT. This could indicate a higher (C)RT-resistance for tumor regions with a high FDG uptake prior to treatment.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21571386     DOI: 10.1016/j.radonc.2011.04.004

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  12 in total

Review 1.  [The role of cross-sectional imaging in staging of rectal cancer].

Authors:  A O Schäfer; M Langer; T Baumann
Journal:  Chirurg       Date:  2012-05       Impact factor: 0.955

Review 2.  Functional MRI for radiotherapy dose painting.

Authors:  Uulke A van der Heide; Antonetta C Houweling; Greetje Groenendaal; Regina G H Beets-Tan; Philippe Lambin
Journal:  Magn Reson Imaging       Date:  2012-07-06       Impact factor: 2.546

3.  High FDG uptake areas on pre-radiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for locally advanced oesophageal cancer.

Authors:  Jérémie Calais; Bernard Dubray; Lamyaa Nkhali; Sebastien Thureau; Charles Lemarignier; Romain Modzelewski; Isabelle Gardin; Frederic Di Fiore; Pierre Michel; Pierre Vera
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-14       Impact factor: 9.236

4.  Changes in cervical cancer FDG uptake during chemoradiation and association with response.

Authors:  Elizabeth A Kidd; Maria Thomas; Barry A Siegel; Farrokh Dehdashti; Perry W Grigsby
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-04-18       Impact factor: 7.038

Review 5.  Validation of functional imaging as a biomarker for radiation treatment response.

Authors:  C Jentsch; B Beuthien-Baumann; E G C Troost; G Shakirin
Journal:  Br J Radiol       Date:  2015-05-29       Impact factor: 3.039

6.  Minicircles for a two-step blood biomarker and PET imaging early cancer detection strategy.

Authors:  Elise R Robinson; Gayatri Gowrishankar; Aloma L D'Souza; Azadeh Kheirolomoom; Tom Haywood; Sharon S Hori; Hui-Yen Chuang; Yitian Zeng; Spencer K Tumbale; Amin Aalipour; Corinne Beinat; Israt S Alam; Ataya Sathirachinda; Masamitsu Kanada; Ramasamy Paulmurugan; Katherine W Ferrara; Sanjiv S Gambhir
Journal:  J Control Release       Date:  2021-05-21       Impact factor: 11.467

7.  18F-deoxyglucose positron emission tomography/computed tomography to predict local failure in esophageal squamous cell carcinoma.

Authors:  Bingjie Fan; Pingping Fan; Li Kong; Xindong Sun; Shuqiang Zhao; Xiaorong Sun; Zheng Fu; Jinsong Zheng; Li Ma; Shijiang Wang; Man Hu; Jinming Yu
Journal:  Oncotarget       Date:  2017-05-23

8.  Impact of suboptimal dosimetric coverage of pretherapeutic 18F-FDG PET/CT hotspots on outcome in patients with locally advanced cervical cancer treated with chemoradiotherapy followed by brachytherapy.

Authors:  François Lucia; Vincent Bourbonne; Dorothy Gujral; Gurvan Dissaux; Omar Miranda; Maelle Mauguen; Olivier Pradier; Ronan Abgral; Ulrike Schick
Journal:  Clin Transl Radiat Oncol       Date:  2020-05-11

9.  Challenges in using ¹⁸F-fluorodeoxyglucose-PET-CT to define a biological radiotherapy boost volume in locally advanced pancreatic cancer.

Authors:  James M Wilson; Somnath Mukherjee; Kwun-Ye Chu; Thomas B Brunner; Mike Partridge; Maria Hawkins
Journal:  Radiat Oncol       Date:  2014-06-24       Impact factor: 3.481

10.  Use of baseline 18F-FDG PET scan to identify initial sub-volumes with local failure after concomitant radio-chemotherapy in head and neck cancer.

Authors:  Floriane Legot; Florent Tixier; Minea Hadzic; Thomas Pinto-Leite; Christelle Gallais; Rémy Perdrisot; Xavier Dufour; Catherine Cheze-Le-Rest
Journal:  Oncotarget       Date:  2018-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.